|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | University Hospital Muenster |
|---|---|
| Information provided by: | University Hospital Muenster |
| ClinicalTrials.gov Identifier: | NCT00111371 |
Purpose
This study aims to determine whether levodopa, in combination with a high frequency training of (grammatical) rules, is effective in boosting learning success in healthy subjects and whether this kind of training in combination with levodopa improves reading and spelling abilities of patients with dyslexia.
| Condition | Intervention | Phase |
|---|---|---|
|
Dyslexia |
Drug: Levodopa |
Phase IV |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment |
| Official Title: | Dopaminergic Enhancement of Learning and Memory (LL_001, Project on Dyslexia) |
| Estimated Enrollment: | 100 |
| Study Start Date: | January 2005 |
| Estimated Study Completion Date: | October 2007 |
Prior work by our group shows that d-amphetamine and the dopamine precursor levodopa markedly improve word learning success in healthy subjects. In this randomized, placebo-controlled, double-blind trial, we probe whether daily administration of levodopa, coupled with a training of grammatical rules, improves the training success in healthy adults as compared to placebo administration. In the second step of this study, patients with dyslexia will be trained with the identical protocol. We postulate that the combination of intensive training in language rules and levodopa improves the reading, writing, and spelling abilities of patients with dyslexia.
Eligibility| Ages Eligible for Study: | 18 Years to 35 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Stefan Knecht, MD | +49-251-83 ext 48195 | knecht@uni-muenster.de |
| Germany | |
| Dept. of Neurology, University Hospital of Muenster | Recruiting |
| Muenster, North-Rhine Westphalia, Germany, 48129 | |
| Contact: Stefan Knecht, Prof. Dr. +49-251-83 ext 48195 knecht@uni-muenster.de | |
| Principal Investigator: Stefan Knecht, M.D. | |
| Principal Investigator: | Stefan Knecht, Prof. Dr. | Dept. of Neurology, Universityclinic of Muenster |
More Information
| ClinicalTrials.gov Identifier: | NCT00111371 History of Changes |
| Other Study ID Numbers: | LL-001; Project on Dyslexia |
| Study First Received: | May 19, 2005 |
| Last Updated: | April 18, 2007 |
| Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
|
artificial grammar learning dyslexia healthy subjects levodopa |
drug treatment intervention |
|
Dyslexia Language Disorders Communication Disorders Neurobehavioral Manifestations Neurologic Manifestations Nervous System Diseases Learning Disorders Signs and Symptoms Mental Disorders Diagnosed in Childhood Mental Disorders Dopamine Dopamine Agents Levodopa Dopamine Agonists |
Cardiotonic Agents Cardiovascular Agents Therapeutic Uses Pharmacologic Actions Sympathomimetics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Protective Agents Antiparkinson Agents Anti-Dyskinesia Agents Central Nervous System Agents |